Skip to content

Study on the Effects of Intravenous Dexmedetomidine on Pain in Patients Undergoing Elective Spinal Surgery

CompletedPhase 4NCT03325972
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

This is a randomized, prospective, double-blind , placebo-controlled trial examining the effects of intraoperative dexmedetomidine infusion on pain in patients undergoing lumbar spinal fusion surgery. One hundred ten subjects (55 in each arm) will be enrolled. Subjects, over the age of 18, undergoing lumbar spinal fusion will be considered eligible for enrollment. Subjects will receive either intraoperative dexmedetomidine or placebo of normal saline infusion. They will be followed for approximately six weeks postoperatively.

Study details

Official title
Randomized, Double-blind, Placebo-controlled Study on the Effects of Intravenous Dexmedetomidine on Pain in Patients Undergoing Elective Spinal Surgery
Conditions
Interventions
Sponsor
NYU Langone Health
Start date
2016-09-14
Primary completion
2022-02-22
Sex
All
Age range
from 18 Years
Results posted
Yes, on ClinicalTrials.gov
Countries
United States
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Adults who will undergo lumbar spinal fusion, including surgeries extending into thoracic and sacral segments * Subject is non-lactating and is either: * Not of childbearing potential * Of childbearing potential but is not pregnant at time of surgery as determined by pre-surgical pregnancy testing * Subject is ASA physical status 1, 2, or 3. Exclusion Criteria: * Subject is pregnant or breastfeeding * Any subject whom the investigators deem unable to complete any/all research related tasks * Subjects who are cognitively impaired (by history) * Subject requires antipsychotic medications * Subject has received treatment with alpha-2 agonists or antagonists within 2 weeks prior to surgery * Subject has known allergy to dexmedetomidine * Subjects with impaired renal or hepatic function * Subjects with advanced heart block * Subjects with severe ventricular dysfunction

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03325972